1-5 of 5
Sarah A. Weiss
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Open Access
Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel-Ángel Berciano-Guerrero, Eva Muñoz Couselo, Delvys Rodríguez-Abreu, Valentina Boni, Lynn M. Schuchter, Maria Gonzalez-Cao, Ana Arance, Wei Wei, Apar Kishor Ganti, Ralph J. Hauke, Alfonso Berrocal, Nicholas O. Iannotti, Frank J. Hsu, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 74–81.
https://doi.org/10.1158/1078-0432.CCR-23-0475
Published: 05 January 2024
View articletitled, A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Open the PDF for A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Available to Purchase
Sarah A. Weiss, Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia Jilaveanu, Amanda Ralabate, Barbara Johnson, Neta Shanwetter Levit, Gail Anderson, Daniel Zelterman, Wei Wei, Amit Mahajan, Ovid Trifan, Marcus Bosenberg, Susan M. Kaech, Curtis J. Perry, William Damsky, Scott Gettinger, Mario Sznol, Michael Hurwitz, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4757–4767.
https://doi.org/10.1158/1078-0432.CCR-21-0903
Published: 01 September 2021
View articletitled, A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Open the PDF for A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1 in another window
Includes: Supplementary data
Journal Articles

Immunotherapy of Melanoma: Facts and Hopes

Free
Sarah A. Weiss, Jedd D. Wolchok, Mario Sznol
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5191–5201.
https://doi.org/10.1158/1078-0432.CCR-18-1550
Published: 03 September 2019
View articletitled, Immunotherapy of Melanoma: Facts and Hopes
Open the PDF for Immunotherapy of Melanoma: Facts and Hopes in another window
Journal Articles

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Free
Curtis H. Kugel, III, Stephen M. Douglass, Marie R. Webster, Amanpreet Kaur, Qin Liu, Xiangfan Yin, Sarah A. Weiss, Farbod Darvishian, Rami N. Al-Rohil, Abibatou Ndoye, Reeti Behera, Gretchen M. Alicea, Brett L. Ecker, Mitchell Fane, Michael J. Allegrezza, Nikolaos Svoronos, Vinit Kumar, Daniel Y. Wang, Rajasekharan Somasundaram, Siwen Hu-Lieskovan, Alpaslan Ozgun, Meenhard Herlyn, Jose R. Conejo-Garcia, Dmitry Gabrilovich, Erica L. Stone, Theodore S. Nowicki, Jeffrey Sosman, Rajat Rai, Matteo S. Carlino, Georgina V. Long, Richard Marais, Antoni Ribas, Zeynep Eroglu, Michael A. Davies, Bastian Schilling, Dirk Schadendorf, Wei Xu, Ravi K. Amaravadi, Alexander M. Menzies, Jennifer L. McQuade, Douglas B. Johnson, Iman Osman, Ashani T. Weeraratna
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (21): 5347–5356.
https://doi.org/10.1158/1078-0432.CCR-18-1116
Published: 01 November 2018
View articletitled, Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
Open the PDF for Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations in another window
Includes: Supplementary data
Journal Articles

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805

Free
Lucia B. Jilaveanu, Maneka Puligandla, Sarah A. Weiss, Xin Victoria Wang, Christopher Zito, Keith T. Flaherty, Marta Boeke, Veronique Neumeister, Robert L. Camp, Adebowale Adeniran, Michael Pins, Judith Manola, Robert S. DiPaola, Naomi B. Haas, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1): 217–223.
https://doi.org/10.1158/1078-0432.CCR-17-1555
Published: 02 January 2018
View articletitled, Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805
Open the PDF for Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805 in another window
Includes: Supplementary data